Compare Anheuser-Busch Inbev SA (BUD) vs Humana Inc (HUM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Anheuser-Busch Inbev SA vs Humana Inc — how do they compare? Anheuser-Busch Inbev SA trades at $79.19 (market cap $159.01B), while Humana Inc trades at $388.25 (market cap $44.77B). The key difference: Anheuser-Busch Inbev SA is far larger — about 3.6× Humana Inc's market cap, and Anheuser-Busch Inbev SA pays the higher dividend (1.67%). Which is the better fit depends on your goals.
| BUD | HUM | |
|---|---|---|
Market Cap | $159.01B | $44.77B |
Sector | Consumer Staples | Health |
52-Week High | $86.48 | $409.42 |
52-Week Low | $57.93 | $163.67 |
Enterprise Value | $223.42B | $52.12B |
Dividend Yield | 1.67% | 0.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BUD trades at $79.20, down 4.69% today, with technical indicators showing bearish momentum. The stock shows solid fundamentals with 2025 revenue of $59.32B and net income margin improving to 11.52%. Recent Q2 2026 earnings beat expectations with EPS of $1.21 versus $1.09 estimate. Analyst consensus remains bullish with 57.8% buy ratings and $90.17 price target, representing 14% upside potential from current levels.
The outlook remains positive given strong cash flow generation and debt reduction trends, though near-term technical weakness and competitive pressures in the beer industry present risks. Institutional activity shows mixed signals with recent share sales by Cetera Investment Advisers offset by Bank of New York Mellon purchases.
Humana (HUM) trades at $388.96, up 0.9% with a neutral technical signal. The stock shows strong revenue growth reaching $129.7B in 2025 but faces margin compression with net income margin declining to 0.88%. Recent earnings beat expectations for three consecutive quarters, while analyst consensus targets $409.93. The company maintains solid cash flow generation and recently announced key leadership appointments to strengthen its Medicaid business.
Humana presents a mixed outlook with robust revenue expansion offset by margin pressures. Investment opportunity lies in Medicare Advantage growth and cost reduction initiatives, while risks include competitive pressures and regulatory changes in healthcare. Wall Street maintains cautious optimism with 39% buy ratings amid margin recovery challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Anheuser-Busch Inbev SA
Anheuser-Busch InBev is the largest brewer in the world and one of the world's top five consumer product companies, as measured by EBITDA. After the SABMiller acquisition, the company's portfolio now contains five of the top 10 beer brands by sales and 18 brands with retail sales over $1 billion. AB InBev was created by the 2008 merger of Belgium-based InBev and U.S.-based Anheuser-Busch. The firm holds a 62% economic interest in Ambev and in 2016 acquired SABMiller.
Read more on BUD →About Humana Inc
Humana is one of the largest private health insurers in the U.S. with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Humana offers employer-based plans primarily for small businesses along with specialty insurance offerings such as dental, vision, and life. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
Read more on HUM →
